Categories
Change Password!
Reset Password!
In adolescents and adults having moderate-to-severe atopic dermatitis, Abrocitinib is effective to prevent flares.
Treatment with Abrocitinib utilizing either induction with 200 mg Abrocitinib followed by maintenance with reduced-dose 100 mg Abrocitinib or continuous dosing with 200 mg Abrocitinib is an efficient and well-tolerated therapeutic strategy in atopic dermatitis-affected people, as deciphered from the post-hoc analysis of phase 3 JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN trial.
Researchers wanted to assess how well people responded to therapy reintroduction following flare, withdrawal, or continuous/reduced-dose Abrocitinib. Adults and adolescents (12–17 years old) with moderate-severe atopic dermatitis responding to 200–mg Abrocitinib induction received either placebo or Abrocitinib (200 mg/100 mg) for 40 weeks of maintenance. Rescue care was given to subjects who flared up while on maintenance.
As found, 655/981 (66.8%) and 145/246 (58.9%) of the 981 adults and 246 adolescents, respectively, responded to induction. The flare occurred during maintenance with 200 mg Abrocitinib (14.9%/16.9%), 100 mg Abrocitinib (42.9%/38.9%), and placebo (75.5%/78.0%) in comparable amounts in both adults and adolescents. Eczema Area and Severity Index (EASI) responses were recaptured by about 28.6%, 25.0%, and 52.9% of adolescents and 34.3%, 33.7%, and 58.0% of adults for the Abrocitinib 200-mg, 100-mg, and placebo groups, respectively.
The Investigator's Global Assessment (IGA) responses were recaptured by 42.9%, 50.0%, and 73.5% of adolescents and 34.3%, 50.6%, and 74.1% of adults. Regardless of age, Abrocitinib exhibited a comparable safety profile; nausea occurrence was greater in adolescents. For both adults and adolescents, Abrocitinib proved helpful in preventing flares.
Journal of Dermatological Treatment
Efficacy and Safety of Abrocitinib Monotherapy in Adolescents and Adults: A Post Hoc Analysis of the Phase 3 JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN Clinical Trial
Carsten Flohr et al.
Comments (0)